Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 2; pp. 374 - 375
Main Author Van Laar, Jan A M
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.02.2024
Ferrata Storti Foundation
Subjects
Cytokine Release Syndrome - drug therapy
Cytokine Release Syndrome - etiology
Humans
Lymphohistiocytosis, Hemophagocytic - drug therapy
Lymphohistiocytosis, Hemophagocytic - etiology
Nitriles
Pyrazoles
Pyrimidines
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
Disclosures
No conflicts of interest to disclose.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2023.283915